[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"content-doc-dcio6acd5589":3},{"user":4,"document":8,"mainDocument":28,"columnUrl":30,"subscription":31,"footer":43,"text":78},{"isAuthenticated":5,"isAdmin":5,"displayName":6,"avatarUrl":6,"nid":6,"groupLevel":7},false,"",-10,{"id":9,"fullTitle":10,"subTitle":6,"url":11,"columnId":12,"columnName":13,"columnUrl":14,"summary":6,"contentHtml":15,"mainContentHtml":6,"posterUrl":16,"createDate":17,"displayDate":18,"displayDateSlash":19,"pageviews":20,"tags":21,"hidden":5,"isSubContent":5,"replyDocOrTargetId":6,"contentType":24,"videoId":6,"liveVideoUrl":6,"duration":25,"price":25,"priceText":26,"priceBadgeText":26,"priceBadgeClass":27,"freeForMinGroupLevel":25,"redirectUrl":6,"readyToStream":5},"dcio6acd5589","为什么美股基因治疗公司FDMT暴涨超40%","\u002Fdoc\u002Fdcio6acd5589","col18178739ee","美股资讯","\u002Fcol\u002Fcol18178739ee","\u003Cp>美股基因治疗公司4D Molecular Therapeutics (FDMT) 宣布了其在研产品4D-150 SPECTRA临床试验的\u003Cspan data-pm-slice=\"1 1 ["para",{"tagName":"p","attributes":{},"namespaceURI":"http:\u002F\u002Fwww.w3.org\u002F1999\u002Fxhtml"}]\">60周\u003C\u002Fspan>积极结果，并同时获得了欧洲药品管理局 EMA对4D-150注册路径的认可，这一消息让FDMT的股价在交易中飙升42%。\u003C\u002Fp>\n\u003Cp>\u003Cimg style=\"display: block; margin-left: auto; margin-right: auto;\" src=\"https:\u002F\u002Fstockwebsiteblob.blob.core.windows.net\u002Fweb-202508-stk\u002F1866355972mceclip0.png\" width=\"521\" height=\"352\">\u003C\u002Fp>\n\u003Cp data-pm-slice=\"2 2 []\">DME是\u003Cspan class=\"\">糖尿病视网膜病变\u003C\u002Fspan>的并发症，是一种高度流行的疾病，具有显著的未满足医疗需求和较差的治疗依从性。该病症的特点是由于血管渗漏导致黄斑区炎症和肿胀，可能导致视力丧失。目前通常采用每4-12周注射一次的抗VEGF药物进行治疗，但患者依从性不佳。\u003C\u002Fp>\n\u003Cp>4D-150作为一种在研药物，其独特之处在于它利用了4DMT专有的治疗性载体进化平台开发的R100眼内载体，旨在通过单次安全的玻璃体腔注射，实现抗VEGF（阿柏西普和抗VEGF-C）在视网膜内的数年持续递送，能够抑制4种血管生成因子，VEGFA、B、C和PlGF。\u003C\u002Fp>\n\u003Cp>\u003Cimg style=\"display: block; margin-left: auto; margin-right: auto;\" src=\"https:\u002F\u002Fmmbiz.qpic.cn\u002Fmmbiz_png\u002FH6t4picSoOw6qDYVCwpPUb6WVhBpgQArdC30ERIfgjlSbCe4MXEq7fmf8VlSpwmicFXqqGOEN5GgJLYTPYJhPqXg\u002F640?wx_fmt=png&from=appmsg&randomid=aw3myqyb&tp=wxpic&wxfrom=5&wx_lazy=1\" alt=\"图片\" width=\"734\" height=\"335\">\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>这一创新设计有望彻底改变目前需要频繁注射的治疗模式，减轻患者的巨大治疗负担，同时保护视力。\u003C\u002Fp>\n\u003Cp>此次在第43届美国视网膜专家学会 (ASRS) 科学年会上公布的SPECTRA 2a期临床试验数据（数据截点为2025年5月2日）显示，4D-150展现出不错的耐受性和持久的临床活性。\u003C\u002Fp>\n\u003Cp>在所有22名接受治疗的患者中，4D-150耐受性良好，在任何时间点或剂量水平下均未观察到眼内炎症。没有受试者需要调整局部\u003Cspan class=\"\">皮质类固醇\u003C\u002Fspan>治疗方案，并且所有患者目前都已停用皮质类固醇。试验中没有报告低眼压、眼内炎、血管炎、\u003Cspan class=\"\">脉络膜渗漏\u003C\u002Fspan>或视网膜动脉阻塞等不良事件，平均眼压均在正常范围内。\u003C\u002Fp>\n\u003Cp>在疗效方面，视力（视觉敏锐度）和解剖学控制（中央视网膜厚度）方面均取得了持续改善。特别是在3期临床试验推荐剂量（3E10 vg\u002F眼）组的9名患者中，患者的最佳矫正视力 (BCVA) 持续提高了9.7个字母，并且通过光学相干断层扫描 (OCT) 测量的中央视网膜厚度 (CST) 持续减少了174微米。表明患者视力的显著改善，视网膜水肿得到了有效控制。\u003C\u002Fp>\n\u003Cp>\u003Cimg style=\"display: block; margin-left: auto; margin-right: auto;\" src=\"https:\u002F\u002Fmmbiz.qpic.cn\u002Fmmbiz_png\u002FH6t4picSoOw6qDYVCwpPUb6WVhBpgQArdr7tTFKBoicV7PZvw8tJg4G4aHSbjPTEKPqFB7J5nXAHHWiaOhj1ia7zicQ\u002F640?wx_fmt=png&from=appmsg&randomid=ekydrqjx&tp=wxpic&wxfrom=5&wx_lazy=1\" alt=\"图片\" width=\"875\" height=\"335\">\u003C\u002Fp>\n\u003Cdiv id=\"page-content\" class=\"rich_media_area_primary\">\n\u003Cdiv class=\"rich_media_area_primary_inner\">\n\u003Cdiv id=\"img-content\" class=\"rich_media_wrp\">\n\u003Cdiv id=\"js_content\" class=\"rich_media_content js_underline_content autoTypeSetting24psection fix_apple_default_style\">\n\u003Cp>4D-150有望大幅度减轻DME患者的治疗负担。在完成阿柏西普（一种标准的抗VEGF药物）负荷剂量注射后，接受3期临床试验推荐剂量4D-150治疗的患者所需的补充注射次数显著减少。\u003C\u002Fp>\n\u003Cp>与预计的标准阿柏西普2mg每8周注射一次的标签方案相比，4D-150在3期临床试验推荐剂量下使治疗负担减少了78%。该剂量组的平均每位患者补充注射次数为1.6次，而较低剂量组为3.7次，预计标准阿柏西普方案则高达7.0次。\u003C\u002Fp>\n\u003Cp>这意味着，3期临床试验推荐剂量组的注射次数比低剂量组少了58%。在3期临床推荐剂量组的9名患者中，有4名患者实现了零注射，而0-1次注射的患者比例则达到5比9。这种依从性设计的产品，有望真正变革DME的治疗方式，为患者带来有意义且持久的视力改善，这对于DME高发的工作年龄人群尤为重要。\u003C\u002Fp>\n\u003Cp>\u003Cimg class=\"rich_pages wxw-img\" src=\"https:\u002F\u002Fmmbiz.qpic.cn\u002Fmmbiz_png\u002FH6t4picSoOw6qDYVCwpPUb6WVhBpgQArdSOYf1remMzy3A7TuqBX9Kz8y83J0ianAh7EBS7OhyOB8zb10BNicJFJg\u002F640?wx_fmt=png&from=appmsg&randomid=8d0h0h7i&tp=wxpic&wxfrom=5&wx_lazy=1\" alt=\"图片\" data-imgfileid=\"100008661\" data-ratio=\"0.38796296296296295\" data-s=\"300,640\" data-src=\"https:\u002F\u002Fmmbiz.qpic.cn\u002Fmmbiz_png\u002FH6t4picSoOw6qDYVCwpPUb6WVhBpgQArdSOYf1remMzy3A7TuqBX9Kz8y83J0ianAh7EBS7OhyOB8zb10BNicJFJg\u002F640?wx_fmt=png&from=appmsg&randomid=8d0h0h7i\" data-type=\"png\" data-w=\"1080\" data-original-style=\"null\" data-index=\"3\" data-before-load-time=\"1754111538013\" data-report-img-idx=\"3\" data-fail=\"0\">\u003C\u002Fp>\n\u003Cp>继美国FDA在2025年1月达成一致后，欧洲药品管理局也确认，结合SPECTRA和\u003Cspan class=\"wx_search_keyword_wrap\">PRISM\u003C\u002Fspan>临床试验数据以及计划中的两项湿性年龄相关性黄斑变性 (湿性AMD) 4FRONT 3期临床试验数据，单一的3期临床试验将足以支持4D-150在DME领域的上市许可申请 (\u003Cspan class=\"wx_search_keyword_wrap\">MAA\u003C\u002Fspan>)。\u003Cimg class=\"rich_pages wxw-img\" src=\"https:\u002F\u002Fmmbiz.qpic.cn\u002Fmmbiz_png\u002FH6t4picSoOw6qDYVCwpPUb6WVhBpgQArdZ8f4owhAZDYFgZia2qEarUKJicWI7ufjZN1cUecgNQpGDZia6VzR8t6Eg\u002F640?wx_fmt=png&from=appmsg&randomid=qaugycrk&tp=wxpic&wxfrom=5&wx_lazy=1\" alt=\"图片\" data-imgfileid=\"100008656\" data-ratio=\"0.35648148148148145\" data-s=\"300,640\" data-src=\"https:\u002F\u002Fmmbiz.qpic.cn\u002Fmmbiz_png\u002FH6t4picSoOw6qDYVCwpPUb6WVhBpgQArdZ8f4owhAZDYFgZia2qEarUKJicWI7ufjZN1cUecgNQpGDZia6VzR8t6Eg\u002F640?wx_fmt=png&from=appmsg&randomid=qaugycrk\" data-type=\"png\" data-w=\"1080\" data-original-style=\"null\" data-index=\"4\" data-before-load-time=\"1754111711946\" data-report-img-idx=\"4\" data-fail=\"0\">\u003C\u002Fp>\n\u003Cp>4D-150作为其主要候选产品，正被开发用于湿性AMD（目前处于3期开发阶段）和DME这两种影响全球数百万患者的致盲性视网膜血管疾病。目前，4DMT的所有产品目前都处于临床或临床前开发阶段，尚未获得任何监管机构的上市批准。\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv id=\"content_bottom_area\">\n\u003Cdiv class=\"adv_keyword_bottom_modal\" data-v-074c4d68=\"\">\n\u003Cdiv class=\"wx_bottom_modal_wrp ad_keyword_bottom_modal_wrap\" tabindex=\"0\" role=\"dialog\" data-v-074c4d68=\"\" aria-modal=\"true\" aria-hidden=\"true\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003Cdiv class=\"rich_media_area_extra\">\n\u003Cdiv class=\"rich_media_area_extra_inner\">\n\u003Cdiv id=\"page_bottom_area\" class=\"has_extra_cnt\">\n\u003Cdiv> \u003C\u002Fdiv>\n\u003Cdiv>\n\u003Cdiv data-v-985896a8=\"\">\n\u003Cdiv id=\"js_cmt_container\" class=\"rich_media_extra rich_media_extra_discuss js_cmt_container rich_media_extra_discuss_initial rich_media_extra_discuss_empty rich_media_extra_discuss_emptybar\" data-v-985896a8=\"\">\n\u003Cdiv data-v-985896a8=\"\">\n\u003Cdiv class=\"comment_primary_area comment_primary_area_pc\" data-v-985896a8=\"\">\n\u003Cdiv class=\"weui-flex__item weui-flex__item_pc\" data-v-985896a8=\"\"> \u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>","https:\u002F\u002Fstockwebsiteblob.blob.core.windows.net\u002Fweb-202508-stk\u002FUploaderm3aezoj3ajv_2025_08_01_22_17_04.jpg","2025-08-02T05:12:58.443","2025.08.02","2025\u002F08\u002F02",51927,[22,23],"FDMT","CRSP","Article",0,"免费","success",{"id":9,"fullTitle":10,"subTitle":6,"url":11,"columnId":12,"columnName":13,"columnUrl":14,"summary":6,"contentHtml":15,"mainContentHtml":6,"posterUrl":16,"createDate":17,"displayDate":18,"displayDateSlash":19,"pageviews":20,"tags":29,"hidden":5,"isSubContent":5,"replyDocOrTargetId":6,"contentType":24,"videoId":6,"liveVideoUrl":6,"duration":25,"price":25,"priceText":26,"priceBadgeText":26,"priceBadgeClass":27,"freeForMinGroupLevel":25,"redirectUrl":6,"readyToStream":5},[22,23],"\u002Fcol\u002Fstocknews",{"visible":5,"marketingHtml":32,"services":33,"recentDocuments":42},"\u003Cfigure class=\"image\">\u003Ca href=\"https:\u002F\u002Fstockwe.com\u002Fdoc\u002Fdcio537efad5\" target=\"_blank\" rel=\"noopener noreferrer\">\u003Cimg style=\"display:block;margin-left:auto;margin-right:auto;\" src=\"https:\u002F\u002Fstockwewebfiles.blob.core.windows.net\u002Fweb-202408-stk\u002F1586109431mceclip0.jpg\">\u003C\u002Fa>\u003C\u002Ffigure>\u003Cdiv class=\"text-center\">\u003Ch2 class=\"card-title mx-auto\">\u003Cbr>\u003Ca target=\"_blank\" rel=\"noopener noreferrer\" href=\"https:\u002F\u002Fstockwe.com\u002Fdoc\u002Fdcio537efad5\">案例介绍：英伟达深度研究报告\u003C\u002Fa>\u003C\u002Fh2>\u003C\u002Fdiv>",[34,38],{"productId":35,"serviceName":36,"priceText":37},"prod_PPxdDdK87QaiLv","月付","$12.95美元",{"productId":39,"serviceName":40,"priceText":41},"prod_PPxeMs3bix1da5","年付","$149.00美元",[],{"links":44,"images":69,"summaryHtml":74,"aboutTitle":75,"aboutHtml":76,"copyrightHtml":77},[45,48,51,54,57,60,63,66],{"label":46,"url":47},"深度报告","\u002Fcol\u002FdepthReport",{"label":49,"url":50},"VIP会员","\u002Fplan",{"label":52,"url":53},"期权推荐","\u002FOption",{"label":55,"url":56},"低价暴涨股","\u002FPenny",{"label":58,"url":59},"常见问题","https:\u002F\u002Fstockwe.com\u002FFAQ",{"label":61,"url":62},"美股课程","\u002Fcol\u002Fvideos",{"label":64,"url":65},"免责声明","\u002Fdisclaimer",{"label":67,"url":68},"联系我们","\u002FContactUs",[70,71,72,73],"https:\u002F\u002Fstockwebsiteblob.blob.core.windows.net\u002Fweb-202509-stk\u002FUploaderzic2tuwsol2_2025_09_11_18_21_07.gif","https:\u002F\u002Fstockwebsiteblob.blob.core.windows.net\u002Fweb-202509-stk\u002FUploadercakzdvydksw_2025_09_03_09_00_56.png","https:\u002F\u002Fstockwebsiteblob.blob.core.windows.net\u002Fweb-202509-stk\u002FUploadergtjyagwvoyk_2025_09_14_08_32_05.png","https:\u002F\u002Fstockwebsiteblob.blob.core.windows.net\u002Fweb-202509-stk\u002FUploader3u0tt4jhlqh_2025_09_23_22_30_48.png","邮箱: buy@TradesMax.com 美国电话 626-378-3637","公司介绍","\u003Cp class=\"MsoNormal\">美股大数据 StockWe.com 是一个美国领先的金融和美股信息大数据提供商，紧盯华尔街金融市场和行情，2008年成立于美国硅谷，创始人是前纽约证券交易所资深分析师Ken，联合多位摩根斯坦利分析师，谷歌 Meta工程师利用AI和大数据，配合十多年美股实战经验和业内量化交易模型，每天处理千万级股票数据：挖掘潜力大牛股，捕捉期权异动大单，实时主力资金流向、机构持仓变化、川普突发新闻，精准买卖信号第一时间发到您手机APP。\u003C\u002Fp>","专业美股投资者都在这里",{"loading":79,"search":80,"searchPlaceholder":80,"hotContent":81,"draft":82,"noData":83,"searchNoData":84,"edit":85,"editVideo":86,"courseContent":87,"more":88,"buyNow":89,"subscribeNow":90,"encoding":91,"paidContent":92},"Loading...","搜索","热门内容","草稿","目前没有任何内容公布","当前检索内容没有数据","编辑","编辑视频","课程内容","更多","立即购买后观看","- 立即订阅 -","视频编码中...","付费内容"]